 TOKYO , Nov. 20, 2022 PRNewswire -- Eisai Co., Ltd. Headquarters: Tokyo, CEO: Haruo Naito, Eisai will present the efficacy, safety and biomarker findings from the companys Phase 3 confirmatory Clarity AD clinical trial for lecanemab development code: BAN2401, an investigational anti-amyloid beta Aβ protofibril antibody for the potential treatment of mild cognitive impairment MCI due to Alzheimers disease AD and mild AD collectively known as early AD with confirmed presence of amyloid pathology in the brain, at the 15th Clinical Trials on Alzheimers Disease CTAD conference. 